Systems and methods for generating retinal precursors - Patents.com

Culturing stem cells on a laminin matrix with defined media differentiates them into retinal progenitor cells, addressing the limitations of undefined protocols and providing a viable treatment for AMD and RP.

JP7583118B2Active Publication Date: 2024-11-13NATIONAL UNIVERSITY OF SINGAPORE
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023104162
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-10-17
Filing Date
2023-06-26
Publication Date
2024-11-13
Estimated Expiration
2038-10-17

AI Technical Summary

Technical Problem

Current treatments for age-related macular degeneration (AMD) and retinitis pigmentosa (RP) lack effective methods to regenerate lost photoreceptors, and existing protocols for stem cell-derived photoreceptors use undefined culture conditions and materials unsuitable for clinical applications.

Method used

Culturing pluripotent stem cells on a laminin matrix containing a mixture of laminin-323 and laminin-521, and using specific cell culture media to differentiate them into retinal progenitor or photoreceptor cells, with genetic profiles identifying distinct subpopulations for therapeutic applications.

Benefits of technology

This method produces retinal progenitor cells suitable for clinical transplantation in a chemically defined and xeno-free environment, overcoming the limitations of undefined matrices and heterogeneity, and provides a promising treatment for AMD and RP.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583118000003
    Figure 0007583118000003
  • Figure 0007583118000004
    Figure 0007583118000004
  • Figure 0007583118000005
    Figure 0007583118000005
Patent Text Reader

Abstract

To provide systems and methods for producing retinal progenitors.SOLUTION: Retinal progenitors and mature photoreceptor cells can be produced by differentiating human embryonic stem cells on a surface having a laminin matrix made of two laminins, where one laminin is laminin-521 and the other laminin is either laminin-323 or laminin-523. Stem cells plated on this substrate can be differentiated using various types of cell culture medium to obtain the retinal progenitors and mature photoreceptor cells. The present disclosure relates to systems and methods for obtaining retinal progenitor cells or retinal photoreceptor cells.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CITED RELATED APPLICATIONS This application claims priority to PCT Application No. PCT / SG2017 / 050520, filed October 17, 2017, which is incorporated by reference in its entirety.

[0002] background The present disclosure relates to systems and methods for generating retinal progenitor cells (e.g., photoreceptor progenitor cells or ganglion progenitor cells) or retinal photoreceptor cells from human pluripotent stem cells. Also disclosed are compositions and matrices for use in such systems and methods. Transplantation of the resulting retinal progenitor cells or retinal photoreceptor cells is further disclosed and included herein. These methods, compositions, and systems including the cells are useful for treating ocular conditions (e.g., macular degeneration (MD) or retinitis pigmentosa (RP)). [Background technology]

[0003] The leading causes of blindness worldwide are age-related macular degeneration (AMD) and retinitis pigmentosa (RP). These two conditions involve the loss of photoreceptors and the underlying retinal pigment epithelium (RPE). Functional interaction between the photoreceptors and the RPE is required to support the visual system. Unfortunately, the human retina does not have the ability to regenerate cells when lost to disease or injury, and there are no effective treatments to reverse retinal degeneration.

[0004] Postmitotic human photoreceptors are not considered to be an ethical and suitable source for human cell replacement because they are only available after 19 weeks of gestation.Existing protocols for stem cell-derived photoreceptors are mainly based on the differentiation of spontaneous embryoid bodies in chemically undefined culture conditions, with the use of Matrigel® to form 3D optic cup or retinal organoids.These 3D organoids are not amenable to transplantation, and such protocols result in heterogeneous retinal cell types with various developmental stages.

[0005] In addition, Matrigel TM Matrigel is a mouse tumor extract that contains several basement membrane proteins (e.g., type IV collagen, perlecan, laminin-111), as well as growth factors and intracellular proteins. TM is heterogeneous, subject to lot-to-lot variation, and contains widely varying amounts of undefined components. TM Cells cultured above also have the potential to acquire the non-human N-glycolylneuraminic acid (Neu5Gc) immunogen, making them unsuitable for clinical application.

[0006] Current treatments include oral medications including antioxidants (e.g., vitamin A palmitate), docosahexaenoic acid (DHA), calcium channel blockers, and lutein / zeaxanthin, but none have shown any efficacy in restoring vision. Summary of the Invention [Means for solving the problem]

[0007] Short Description The present disclosure relates to a system and method for obtaining retinal progenitor cells or retinal photoreceptor cells. Briefly, pluripotent stem cells are cultured on a substrate containing a mixture of (i) laminin-323 (LN-323) or LN-523, and (ii) laminin-521. LN-323 and LN-523 have not previously been purified in pure form and were first produced as recombinant human proteins in human embryonic kidney cells (HEK-293), purified, and used as cell culture coatings. The stem cells are differentiated using two different cell culture media to obtain retinal progenitor cells or retinal photoreceptor cells (depending on the length of time they are differentiated).

[0008] Five distinct subpopulations of retinal progenitor cells have also been identified, which can be distinguished by genetic profiling at days 26-34, as further described herein.

[0009] In the first subpopulation (A), at least one of the genes CRX, C11orf96, NXPH4, NTS, DCT, PRDM1, NEUROD4, S100A13, RCVRN, FAM57B, SYT4, DLL3, SSTR2, CHRNA5, and ROBO2 are expressed in the gene profile from day 26 to 34. Desirably, many or most of these genes are expressed.

[0010] In the second subpopulation (B), at least one of the genes STMN2, ONECUT2, ATOH7, ELAVL4, and GAP43 are expressed in the gene profile from day 26 to 34. Desirably, many or most of these genes are expressed.

[0011] In a third subpopulation (C), at least one of the genes CNTN2, NEFM, NEFL, PRPH, POU4F2, and CXCR4 is expressed in the gene profile from day 26 to 34. Desirably, many or most of these genes are expressed.

[0012] In a fourth subpopulation (D), at least one of the genes PAX6, SIX3, and SLC2A1 are expressed in the gene profile from day 26 to 34. Desirably, many or most of these genes are expressed.

[0013] In a fifth subpopulation (E), at least one of the genes VSX2, PTH2, FZD5, RARRES2, DIO3, SOX2, and CYP1B1 is expressed in the gene profile from day 26 to 34. Desirably, many or most of these genes are expressed.

[0014] These and other non-limiting features of the present disclosure are disclosed in greater detail below. In an embodiment of the present invention, for example, the following items are provided: (Item 1) retinal progenitor cells, wherein the genetic profile at day 26-34 comprises: (A) at least one of the genes CRX, C11orf96, NXPH4, NTS, DCT, PRDM1, NEUROD4, S100A13, RCVRN, FAM57B, SYT4, DLL3, SSTR2, CHRNA5, and ROBO2 is expressed; or (B) at least one of the genes STMN2, ONECUT2, ATOH7, ELAVL4, and GAP43 is expressed; or (C) at least one of the genes CNTN2, NEFM, NEFL, PRPH, POU4F2, and CXCR4 is expressed; or (D) at least one of the genes PAX6, SIX3, and SLC2A1 is expressed; or (E) at least one of the genes VSX2, PTH2, FZD5, RARRES2, DIO3, SOX2, and CYP1B1 is expressed; Indicated, retinal progenitor cells. (Item 2) The genetic profile from days 26 to 34 was (A) at least two of the genes CRX, C11orf96, NXPH4, NTS, DCT, PRDM1, NEUROD4, S100A13, RCVRN, FAM57B, SYT4, DLL3, SSTR2, CHRNA5, and ROBO2 are expressed; or (B) at least two of the genes STMN2, ONECUT2, ATOH7, ELAVL4, and GAP43 are expressed; or (C) at least two of the genes CNTN2, NEFM, NEFL, PRPH, POU4F2, and CXCR4 are expressed; or (D) at least two of the genes PAX6, SIX3, and SLC2A1 are expressed; or (E) at least two of the genes VSX2, PTH2, FZD5, RARRES2, DIO3, SOX2, and CYP1B1 are expressed; 2. The retinal progenitor cell according to item 1, (Item 3) The gene profile from day 26 to day 34 indicates that the gene CRX or C11orf96 is expressed; and The gene profile from day 26 to day 34 indicates that (i) CRX is expressed at at least 5 gene counts per million, or (ii) C11orf96 is expressed at at least 5 gene counts per million, Item 1. The retinal progenitor cell according to item 1. (Item 4) 4. The retinal progenitor of item 3, wherein the genetic profile at day 26 to day 34 indicates that (i) CRX is expressed at at least 10 gene counts per million, or (ii) C11orf96 is expressed at at least 10 gene counts per million. (Item 5) The gene profile from day 26 to day 34 indicates that the gene STMN2 or ONECUT2 is expressed; and The gene profile from day 26 to day 34 indicates that (i) STMN2 is expressed at at least 5 gene counts per million, or (ii) ONECUT2 is expressed at at least 5 gene counts per million. Item 1. The retinal progenitor cell according to item 1. (Item 6) The retinal progenitor cell of item 5, wherein the gene profile at day 26 to day 34 indicates that (i) STMN2 is expressed at at least 10 gene counts per million, or (ii) ONECUT2 is expressed at at least 10 gene counts per million. (Item 7) The gene profile from day 26 to day 34 indicates that the gene CNTN2 or POU4F2 is expressed; and The gene profile from day 26 to day 34 indicates that (i) CNTN2 is expressed at at least 5 gene counts per million, or (ii) POU4F2 is expressed at at least 5 gene counts per million. Item 1. The retinal progenitor cell according to item 1. (Item 8) 8. The retinal progenitor cell of item 7, wherein the gene profile at day 26 to day 34 indicates that (i) CNTN2 is expressed at at least 10 gene counts per million, or (ii) POU4F2 is expressed at at least 10 gene counts per million. (Item 9) The genetic profile from day 26 to day 34 indicates that the genes PAX6 or SIX3 are expressed; and the gene profile from day 26 to day 34 indicates that (i) PAX6 is expressed at least 5 gene counts per million; or (ii) SIX3 is expressed at least 5 gene counts per million; Item 1. The retinal progenitor cell according to item 1. (Item 10) 10. The retinal progenitor cell of item 9, wherein the gene profile at day 26 to day 34 indicates that (i) PAX6 is expressed at at least 10 gene counts per million, or (ii) SIX3 is expressed at at least 10 gene counts per million. (Item 11) The genetic profile from day 26 to day 34 indicates that the genes VSX2 or CYP1B1 are expressed; and the profile from day 26 to day 34 showing that (i) VSX2 is expressed at at least 5 gene counts per million; or (ii) CYP1B1 is expressed at at least 5 gene counts per million; Item 1. The retinal progenitor cell according to item 1. (Item 12) 12. The retinal progenitor cell of item 11, wherein the gene profile at day 26 to day 34 indicates that (i) VSX2 is expressed at at least 10 gene counts per million, or (ii) CYP1B1 is expressed at at least 10 gene counts per million. (Item 13) 2. The retinal progenitor cell of item 1, wherein the gene profile at days 16-24 indicates that at least one of the genes DAPL1, SIX6, SFRP2, LHX2, PAX6, CDH2, CLDN1, TRPM3, RELN, DCT, and PMEL is expressed. (Item 14) 14. The retinal progenitor cell of item 13, wherein the gene profile on days 16 to 24 indicates that at least one of the genes SIX6, SFRP2, LHX2, PAX6, DCT, or PMEL is expressed. (Item 15) 14. The retinal progenitor cell of item 13, wherein the gene profile on days 16 to 24 indicates that PAX6 is expressed. (Item 16) 1. A method for generating a population of retinal progenitors, the method comprising: plating pluripotent human stem cells onto a cell culture surface having a laminin matrix, wherein the laminin matrix comprises (i) a first laminin selected from the group consisting of laminin-323 and laminin-523, and (ii) a second laminin that is laminin-521, wherein the first laminin and the laminin-521 are each either an intact protein or a protein fragment; culturing the pluripotent human stem cells to obtain retinal progenitors; The population of retinal progenitors is subjected to the steps of: (i) preparing a genetic profile at days 16-24 and selecting retinal progenitors in which at least one of the genes DAPL1, SIX6, SFRP2, LHX2, PAX6, CDH2, CLDN1, TRPM3, RELN, DCT, and PMEL is expressed; and (ii) preparing a genetic profile at days 26-34. (A) at least one of the genes CRX, C11orf96, NXPH4, NTS, DCT, PRDM1, NEUROD4, S100A13, RCVRN, FAM57B, SYT4, DLL3, SSTR2, CHRNA5, and ROBO2 is expressed; or (B) at least one of the genes STMN2, ONECUT2, ATOH7, ELAVL4, and GAP43 is expressed; or (C) at least one of the genes CNTN2, NEFM, NEFL, PRPH, POU4F2, and CXCR4 is expressed; or (D) at least one of the genes PAX6, SIX3, and SLC2A1 is expressed; or (E) at least one of the genes VSX2, PTH2, FZD5, RARRES2, DIO3, SOX2, and CYP1B1 is expressed; identifying by a selection step a retinal precursor; The method includes: (Item 17) 17. The method of claim 16, wherein the weight ratio of the first laminin to the second laminin is about 1:1 to about 4:1. (Item 18) The pluripotent human stem cells are culturing the cells for a first period of time in a neural induction medium comprising a TGFβ inhibitor and a Wnt inhibitor; and culturing the cells for a second period of time in a photoreceptor differentiation medium comprising brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), retinoic acid, and a gamma secretase inhibitor; 17. The method according to item 16, wherein the culture is performed by culturing the strain. (Item 19) Item 19. The method according to item 18, wherein the first period of time is from about 120 hours to about 168 hours. (Item 20) Item 19. The method according to item 18, wherein the second period of time is from about 288 hours to about 816 hours. (Item 21) 19. The method of claim 18, wherein the neural induction medium comprises a TGFβ inhibitor and a Wnt inhibitor. (Item 22) The neural induction medium comprises: about 5 μM to about 15 μM of the TGFβ inhibitor; and About 5 μM to about 15 μM of the Wnt inhibitor 22. The method according to claim 21, comprising: (Item 23) The TGFβ inhibitor is SB431542; or The Wnt inhibitor is CKI-7. Item 22. The method according to item 21. (Item 24) The photoreceptor differentiation medium comprises: about 1 ng / mL to about 20 ng / mL of the brain-derived neurotrophic factor (BDNF); about 1 ng / mL to about 30 ng / mL of the ciliary neurotrophic factor (CNTF); about 0.1 μM to about 5 μM of the retinoic acid; and about 5 μM to about 15 μM of the gamma secretase inhibitor; 19. The method according to item 18, comprising: (Item 25) 19. The method of claim 18, wherein the gamma secretase inhibitor is DAPT. [Brief description of the drawings]

[0015] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0016] The following is a brief description of the drawings, which are shown for purposes of illustrating, but not limiting, the exemplary embodiments disclosed herein.

[0017] [Figure 1A]FIG. 1A is a flow chart describing steps for producing recombinant laminin-523 and laminin-323 in some methods of the disclosure.

[0018] [Figure 1B] FIG. 1B is a Western blot showing the presence of LAMA5, LAMB2, and LAMC3 chains in purified fractions or portions of LN-523.

[0019] [Figure 1C] FIG. 1C is a chromatogram illustrating the protein elution profile of the LN-523 clone using the AKTA Chromatography System.

[0020] [Figure 1D] FIG. 1D is an LC-MS / MS (liquid chromatography-mass spectrometry) result showing the presence of LAMA5, LAMB2, and LAMC3 chains.

[0021] [Figure 1E] FIG. 1E is a Western blot showing the presence of LAMA3, LAMB2, and LAMC3 chains in purified fractions or portions of LN-323.

[0022] [Figure 1F] FIG. 1F is a chromatogram illustrating the protein elution profile of the LN-323 clone using the AKTA Chromatography System.

[0023] [Figure 1G] FIG. 1G shows LC-MS / MS (liquid chromatography-mass spectrometry) results showing the presence of LAMA3, LAMB2, and LAMC3 chains.

[0024] [Figure 2A]Figure 2A is a diagram showing how hESCs are differentiated into photoreceptors. Three cell cultures are shown: Nutristem (day 0) for culture prior to differentiation; neural induction medium; and photoreceptor differentiation medium. Three photographs showing cells at D0, D20, and D30 are also provided.

[0025] [Figure 2B] Figures 2B and 2C are a set of five different graphs of cells grown on LN-523+LN-521 substrates. In the top graph of Figure 2B, the y-axis is in arbitrary units and runs from 0 to 0.15 in increments of 0.05. The x-axis, from left to right, are OCT3 / 4, NANOG, BRA, MIXL1, SOX17, FOXA2, and PAX6.

[0026] In the bottom left graph of FIG. 2B labeled PAX6, the y-axis is in arbitrary units and runs from 0 to 0.18 in increments of 0.02, and the x-axis is, from left to right: D0 LN-523+LN-521, D20 LN-523+LN-521, D20 LN-523 only, D30 LN-523+LN-521, and D30 LN-523 only.

[0027] In the bottom right graph of Figure 2B, labeled VSX2, the y-axis is in arbitrary units and runs from 0 to 0.06 in increments of 0.01. The x-axis, from left to right, is: D0 LN-523+LN-521, D20 LN-523+LN-521, D20 LN523 only, D30 LN523+521, and D30 LN523 only.

[0028] [Figure 2C] In the left graph of Figure 2C, labeled CRX, the y-axis is in arbitrary units and runs from 0 to 0.0045 in increments of 0.0005. The x-axis, from left to right, is: D0 LN523+521, D20 LN523+521, D20 LN523 only, D30 LN-523+LN-521, and D30 LN-523 only.

[0029] In the right graph of Figure 2C labeled RCVRN, the y-axis is in arbitrary units and runs from 0 to 0.025 in increments of 0.005, and the x-axis is, from left to right, D0 LN-523+LN-521, D20 LN-523+LN-521, D20 LN-523 only, D30 LN-523+LN-521, and D30 LN-523 only.

[0030] [Figure 2D] Figures 2D and 2E are a set of five different graphs of cells grown on LN-323+LN-521 substrates. In the top graph of Figure 2D, the y-axis is in arbitrary units and runs from 0 to 0.15 in increments of 0.05. The x-axis, from left to right, are OCT3 / 4, NANOG, BRA, MIXL1, SOX17, FOXA2, and PAX6.

[0031] In the bottom left graph of Figure 2D labeled PAX6, the y-axis is in arbitrary units and runs from 0 to 0.16 in increments of 0.02, and the x-axis is, from left to right, D0 LN-323+LN-521, D20 LN-323+LN-521, D20 LN-323 only, D30 LN-323+LN-521, and D30 LN-323 only.

[0032] In the bottom right graph of Figure 2D labeled VSX2, the y-axis is in arbitrary units and runs from 0 to 0.05 in increments of 0.005, and the x-axis is, from left to right, D0 LN-323+LN-521, D20 LN-323+LN-521, D20 LN-323 only, D30 LN-323+LN-521, and D30 LN-323 only.

[0033] [Figure 2E] In the left graph of Figure 2E labeled CRX, the y-axis is in arbitrary units and runs from 0 to 0.0014 in increments of 0.0002. The x-axis, from left to right, is: D0 LN-323+LN-521, D20 LN323+LN-521, D20 LN-323 only, D30 LN-323+LN-521, and D30 LN-323 only.

[0034] In the right graph of Figure 2E, labeled RCVRN, the y-axis is in arbitrary units and runs from 0 to 0.0008 in increments of 0.0001, and the x-axis, from left to right, is D0 LN-323+LN-521, D20 LN-323+LN-521, D20 LN-323 only, D30 LN-323+LN-521, and D30 LN-323 only.

[0035] [Figure 2F] Figures 2F and 2G are a set of five different graphs of cells grown on LN-521 only substrates. In the top graph of Figure 2F, the y-axis is in arbitrary units and runs from 0 to 0.2 in increments of 0.05. The x-axis, from left to right, is OCT3 / 4, NANOG, BRA, MIXL1, SOX17, FOXA2, and PAX6.

[0036] In the bottom left graph of Figure 2F labeled PAX6, the y-axis is in arbitrary units and runs from 0 to 0.12 in increments of 0.02. The x-axis, from left to right, is D0 LN-521, D20 LN-521, and D30 LN-521.

[0037] In the bottom right graph of Figure 2F, labeled VSX2, the y-axis is in arbitrary units and runs from 0 to 0.025 in increments of 0.005. The x-axis, from left to right, is D0 LN-521, D20 LN-521, and D30 LN-521.

[0038] [Figure 2G] In the bottom left graph of Figure 2G, labeled CRX, the y-axis is in arbitrary units and runs from 0 to 0.0025 in increments of 0.0005. The x-axis, from left to right, is D0 LN521, D20 LN-521, and D30 LN-521.

[0039] In the bottom left graph of Figure 2G, labeled RCVRN, the y-axis is in arbitrary units and runs from 0 to 0.003 in increments of 0.005. The x-axis, from left to right, is D0 LN-521, D20 LN-521, and D30 LN-521.

[0040] [Figure 3A] Figures 3A-3C are a set of photographs showing immunocytochemical analysis of D0 undifferentiated hESC and D38 hESC-derived retinal cells. Figure 3A is for cells grown on LN-523+LN-521 substrate. Figure 3B is for cells grown on LN-523+LN-521 substrate. Figure 3C is for cells grown on LN-521 only substrate. Each set contains 10 micrographs (scale bar = 20 μm). In each set, the top row shows the analysis of D0 cells for OCT4, D0 cells for PAX6, and D38 cells for PAX6. The second row shows these composited with DAPI. The third row shows the analysis of D38 cells for VSX2 and D38 cells for RCVRN. The fourth row shows these composited with DAPI. D0 Undifferentiated stem cells express OCT4 but not PAX6 (Paired box 6). D38 Differentiated cells express the markers PAX6, VSX2, and RCVRN. [Figure 3B] Same as above. [Figure 3C] Same as above.

[0041] [Figure 3D] FIG. 3D is a bar graph comparing expression of the markers PAX6, VSX2, CRX, and RCVRN on three laminin matrices. The y-axis is in arbitrary units and runs from 0 to 100 in increments of 20. On the x-axis, from left to right, the markers are PAX6, VSX2, CRX, and RCVRN. For each marker, the left bar is expression on the LN-523:LN-521 substrate. The middle bar is for the LN-323:LN-521 substrate, and the right bar is for the LN-521 only substrate.

[0042] [Figure 4A]Figure 4A is a t-distributed stochastic neighbor embedding algorithm (t-SNE) visualization of NANOG expression levels for all day 20 retinal progenitor cells profiled by single-cell RNA sequencing (t-SNE dimensions 1 and 2, x-axis and y-axis, respectively). Each dot represents a cell. "Log2 Adj. count" refers to the Log2 scran normalized and cell cycle adjusted gene count of NANOG. NANOG gene counts range from 0 to 2.21.

[0043] [Figure 4B] Figure 4B is a t-SNE visualization of POU5F1 expression levels for all day 20 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. POU5F1 gene counts range from 0 to 1.33.

[0044] [Figure 4C] (C) t-SNE visualization of PAX6 expression levels for all day 20 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. PAX6 gene counts range from -0.36 to 5.87.

[0045] [Figure 4D] (D) t-SNE visualization of LHX2 expression levels for all day 20 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. LHX2 gene counts range from -0.54 to 5.00.

[0046] [Diagram 5]Figure 5 is a heatmap showing gene-gene expression (profiled by single-cell RNA sequencing) pairwise correlation levels of marker genes identified for the subpopulation of day 20 retinal progenitor cells expressing PAX6. This gene-gene expression pairwise correlation is calculated across all day 20 retinal progenitor cells profiled by single-cell sequencing and that passed the quality control step. Level bars indicate gene-gene expression pairwise Pearson correlations and range from -1 to 1.

[0047] [Figure 6] Figure 6 is a heat map showing gene-gene expression (profiled by single-cell RNA sequencing) pairwise correlation levels of marker genes identified for each of the five subpopulations of cells identified in all day 30 retinal progenitor cells. The gene-gene expression pairwise correlation is calculated across all day 30 retinal progenitor cells profiled by single-cell sequencing and passed the quality control step. From top to bottom, the five cell subpopulations are indicated as follows: CRX+, STMN2+, CNTN2+, PAX6+ and VSX2+. Marker genes belonging to distinct cell subpopulations are separated by lines. Genes naming each of the five cell subpopulations are indicated by arrows. The level bars indicate gene-gene expression pairwise Pearson correlations, ranging from -1 to 1.

[0048] For reference, the vertical list of genes on the right side of Figure 6 is shown as follows (top to bottom): C11orf96; NXPH4; NTS; DCT; PRDM1; NEUROD4; CRX; S100A13; RCVRN; FAM57B; SYT4; DLL3; SSTR2; CHRNA5; ROBO2; ONECUT2; ATOH7; STMN2; ELAVL4; GAP43; NEFM; NEFL; PRPH; CNTN2; POU4F2; CXCR4; SIX3; PAX6; SLC2A1; PTH2; FZD5; VSX2; RARRES2; DIO3; SOX2; and CYP1B1. The horizontal list of genes on the bottom of Figure 6 is the same when read from right to left.

[0049] [Figure 7A] Figure 7A is a t-distributed stochastic neighbor embedding algorithm (t-SNE) visualization of CRX expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing (t-SNE dimensions 1 and 2, x-axis and y-axis, respectively). Each dot represents a cell. Log2 adjusted counts refer to Log2 scran normalized and cell cycle adjusted gene counts. CRX gene counts range from -0.05 to 3.33.

[0050] [Figure 7B] Figure 7B is a t-SNE visualization of C11orf96 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. C11orf96 gene counts range from -0.25 to 5.15.

[0051] [Figure 7C] (C) t-SNE visualization of STMN2 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. STMN2 gene counts range from -0.92 to 6.52.

[0052] [Figure 7D] Figure 7D is a t-SNE visualization of ONECUT2 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. ONECUT2 gene counts range from -0.80 to 4.81.

[0053] [Figure 7E] (E) t-SNE visualization of CNTN2 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. CNTN2 gene counts range from -0.24 to 5.35.

[0054] [Figure 7F] (F) t-SNE visualization of POU4F2 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. POU4F2 gene counts range from -0.14 to 4.47.

[0055] [Figure 7G] Figure 7G is a t-SNE visualization of PAX6 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. PAX6 gene counts range from 0 to 5.68.

[0056] [Figure 7H] (H) t-SNE visualization of SIX3 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. SIX3 gene counts range from 0 to 4.63.

[0057] [Figure 7I]Figure 7I is a t-SNE visualization of VSX2 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. VSX2 gene counts range from -0.17 to 3.28.

[0058] [Figure 7J] (J) t-SNE visualization of CYP1B1 expression levels for all day 30 retinal progenitor cells profiled by single-cell RNA sequencing. Each dot represents a cell. CYP1B1 gene counts range from -0.23 to 6.01. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0059] Detailed Description A more complete understanding of the compositions and methods disclosed herein may be obtained by reference to the accompanying drawings, which are merely schematic representations for convenience and ease of illustrating the disclosure, and are therefore not intended to define or limit the scope of the exemplary embodiments.

[0060] Although specific terms are used in the following description for purposes of clarity, these terms are intended only to refer to the particular structures of the embodiments selected for illustration in the drawings, and are not intended to define or limit the scope of the present disclosure. It should be understood that in the drawings and the description that follows, like numeral designations refer to components of similar function.

[0061] All publications, patents, and patent applications discussed herein are incorporated by reference in their entirety.

[0062] The singular forms "a," "an," and "this," "the" include the plural forms unless the context clearly dictates otherwise.

[0063] As used in the specification and claims, the term "comprising" can include "consisting of" and "consisting essentially of" embodiments. The terms "comprise(s)", "including(s)", "having", "has", "can", "contain(s)", and variations thereof, as used herein, are intended to be open-ended transitional phrases, terms, or phrases that require the presence of the recited components / steps and permit the presence of others. However, such descriptions should also be construed to describe the composition or process as "consisting of" and "consisting essentially of" the recited components / steps, permitting the presence of only the recited components / steps along with any impurities that may result therefrom, and to the exclusion of other components / steps.

[0064] Numerical values ​​in the specification and claims of this application should be understood to include numerical values ​​that are the same when reduced to the same number of significant digits to determine that numerical value and numerical values ​​that differ from the stated value within less than experimental error of conventional measuring techniques of the type described in this application.

[0065] All ranges disclosed herein are inclusive of their recited endpoints and are independently combinable (e.g., the range "from 2 to 10" includes its endpoints of 2 and 10, as well as all values ​​in between).

[0066] The term "about" can be used to include any numerical value that can vary without changing the fundamental function of its value. When used in conjunction with a range, "about" also discloses a range defined by the absolute values ​​of its two endpoints, for example, "about 2 to about 4" also discloses the range "2 to 4". The term "about" can refer to ±10% of the indicated number.

[0067] Some well-known references that may be relevant to the present disclosure include: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, D. Goeddel, ed., 1991. Academic Press, San Diego, Calif.), "Guide to Protein Purification" in Methods in Enzymology (MP Deutschcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, Calif.), Culture of Animal Cells: A Manual of Basic Technique, 2nd Edition. (RI Freshney. 1987. Liss, Inc. New York, NY), Gene Transfer and Expression Protocols, pp. 109-128, EJ Murray, ed., The Humana Press Inc., Clifton, NJ), or the Ambion 1998 catalogue (Ambion, Austin, Tex.); Functional Diversity of Laminins, Domogatskaya, A, Rodin, S and Tryggvason, K,. Annu. Rev. Cell Dev. Biol. 2012, 28, 523-553.

[0068] Laminin protein contains one α-chain subunit, one β-chain subunit, and one γ-chain subunit, all linked together in a trimer through a coiled-coil domain. The 12 known laminin subunit chains can theoretically form at least 60 different isoforms. Currently, 16 trimeric laminin types have been identified in natural mammalian tissues. Within the trimeric laminin structure, domains with binding activity to other laminin molecules and basal laminin molecules, as well as cytoplasmic membrane-bound receptors, are identifiable. For example, domains VI, IVb, and IVa form a ball-shaped structure, while domains V, IIIb, and IIIa (which contain a cysteine-rich EGF-like element) form a rod-like structure. Domains I and II at the C-terminus of the three chains are involved in the formation of a triple-stranded coiled-coil structure (long arm). There are five genetically distinct α-chains, three β-chains, and three γ-chains, which are found in human tissues in at least 16 different combinations. One nomenclature for these laminin proteins describes isoforms based on their chain composition (eg, laminin-111 contains α1, β1, and γ1 chains).

[0069] As used herein, the term "laminin-323" (LN-323) refers to a protein formed by the α3, β2 and γ3 chains joining together. As used herein, the term "laminin-521" (LN-521) refers to a protein formed by the α5, β2 and γ1 chains joining together. As used herein, the term "laminin-523" (LN-523) refers to a protein formed by the α5, β2 and γ3 chains joining together. These terms should be interpreted to encompass both recombinant laminins and heterotrimeric laminins from naturally occurring sources. The term "recombinant" indicates that the protein is artificially produced using an expression plasmid in a cell that does not normally express such a protein.

[0070] Laminin can be a complete protein trimer, or a protein chain, or a protein fragment. The term "complete" refers to a protein composed of an α chain, one β chain, and all three chains bound together to form the heterotrimeric structure. The protein is not degraded into separate chains, fragments, or functional domains. The term "chain" refers to the individual α, β, or γ chain entities of the laminin protein. The term "fragment" refers to any protein fragment that contains one, two, or three functional domains that have binding activity to another molecule or receptor. However, a chain should not be considered a fragment since each chain has more than three such domains. Similarly, a complete laminin protein trimer should not be considered a fragment. Examples of functional domains include domains I, II, III, IV, V, VI, and G domain. Further information regarding these domains can be found in Domogatskaya, A., Rodin, S., and Tryggvason, K. 2012. Functional diversity of laminins. Annu Rev Cell Dev Biol 28:523-553, which is incorporated by reference.

[0071] The present disclosure relates to a method for culturing and differentiating pluripotent stem cells to obtain retinal progenitor cells (e.g., photoreceptor progenitor cells or progenitor ganglion cells) or retinal photoreceptors. In particular, stem cells are cultured on a laminin matrix that contains only two laminin isoforms. The first laminin in the laminin matrix is ​​LN-323 or LN-523, which are located in the matrix surrounding retinal photoreceptors in vivo. The second laminin in the laminin matrix is ​​LN-521. Alternatively, the laminin matrix may contain only a single laminin, which is laminin-521. The stem cells are then exposed to two specific cell culture media. This results in photoreceptors derived from pluripotent stem cells that are more suitable for clinical application than cells grown on substrates that contain undefined, heterogeneous and alternative blends of extracellular matrices.

[0072] Differentiated cells typically require two things to survive and reproduce: (1) a substrate that provides structural and phenotypic stabilizing support for the cells; and (2) a cell culture medium that provides nutrients to the cells. Very commonly, the pluripotent stem cells are cultured on a laminin matrix that can be attached to a solid surface, which acts as a structural support and also maintains the pluripotent phenotype. The term "solid" refers to the state of matter. That is, the substrate is not a liquid or a gas or a plasma. The surface can be rigid / hard or very flexible (e.g., a film), and the term "solid" should not be interpreted as requiring a particular degree of rigidity. The surface (1) is typically a container, e.g., a petri dish, or in the well of a multi-well plate. The laminin matrix is ​​in the form of a substrate (i.e., a layer or coating) on ​​the surface. In combination with substrates containing two laminins, application of different cell culture media for appropriate time intervals results in differentiated photoreceptors (either as precursor cells or as mature cells).

[0073] The stem cell that can be used with the methods and materials disclosed herein is pluripotent human stem cell.Such stem cell can include induced pluripotent stem cell, embryonic stem cell, adult stem cell, fetal stem cell, amniotic stem cell, and generally any pluripotent stem cell.Stem cell is an undifferentiated cell from which specialized cells are subsequently obtained.Pluripotency refers to a cell that has the potential to differentiate into cells of all three germ layers.

[0074] In some embodiments, the laminin matrix comprises a mixture of two laminins. The laminin matrix contains only two laminin trimers / chains / fragments, but allows other components to still be present in the laminin matrix. The first laminin is either laminin-323 (LN-323) or laminin-523 (LN-523). The second laminin is laminin-521 (LN-521). Each laminin can be an intact protein or a protein fragment, but in preferred embodiments the laminin is an intact protein.

[0075] In certain embodiments, the laminin-323 / 523 pair in the laminin matrix The weight ratio of laminin-521 is contemplated to be about 1:1 to about 4:1, including about 1:1 to about 2:1 (i.e., always less laminin-521 than laminin-323 / 523). In particular, laminin-323 and laminin-523 are present in the outer limiting membrane spanning the rods and cones of the retina, and laminin-523 is present in Bruch's membrane located beneath the RPE. Their presence is believed to drive differentiation of stem cells into retinal lineage-specific cells.

[0076] In other embodiments, the laminin matrix contains only a single laminin, which is laminin-521. Other components (other than laminin) may still be present in the laminin matrix.

[0077] The cell culture substrate is used in combination with a number of cell culture media to obtain the desired retinal progenitor cells or photoreceptor cells. Two different cell culture media are used, which are described below and are referred to herein as neural induction medium and photoreceptor differentiation medium.

[0078] Both the neural induction medium and the photoreceptor differentiation medium begin with a basal medium, which consists of Glasgow Minimum Essential Medium (GMEM), which is commercially available from ThermoFisher Scientific (catalog number 11710035). The GMEM is supplemented with 0.1 mM β-mercaptoethanol, 1× non-essential amino acid solution (Gibco catalog number 11140050 (provided as 100×)), and 1 mM pyruvate to make the basal medium.

[0079] For reference, GMEM contains the following components listed in Table 1: [Table 1]

[0080] A 1× Non-Essential Amino Acid Solution contains the following components at the concentrations listed in Table 2: [Table 2]

[0081] The neural induction medium and photoreceptor differentiation medium are made by mixing a volume of the basal medium with other additives. One such additive is B27 Vitamin A-free supplement, which can be obtained from Thermo Fisher (catalog number 12587010, provided at 50x). Another additive is N2 supplement, which can be obtained from Thermo Fisher (catalog number A1370701, provided at 100x). Other additives include human brain-derived neurotrophic factor (BDNF), human ciliary neurotrophic factor (CNTF), retinoic acid, TGFβ inhibitors (e.g., SB431542 (CAS# 301836-41-9)), gamma-secretase inhibitors (e.g., DAPT). BDNF can be obtained from Peprotech (catalog number 450-02). Wnt inhibitors (e.g., CKI-7). CNTF can be obtained from Prospec-Tany Technogene (catalog number CYT-272). DAPT can be obtained from Selleckchem (catalog number S2215). CKI-7 can be obtained from Sigma (CAS# 1177141-67-1, catalog number C0742).

[0082] The neural induction medium is made by mixing 97 parts by volume (pbv) of basal medium with 2 pbv of B27 vitamin A-free supplement and 1 pbv of N2 supplement, and then adding a TGF-β inhibitor (e.g., SB431542) and a Wnt inhibitor. The TGF-β inhibitor is present at a concentration of about 1 μM to about 10 μM, particularly about 5 μM. In a specific embodiment, the TGF-β inhibitor is SB431542. The Wnt inhibitor is present at a concentration of about 1 μM to about 10 μM, particularly about 5 μM. In a specific embodiment, the Wnt inhibitor is CKI-7. The neural induction medium does not include growth factors, such as BDNF, CNTF, or gamma secretase inhibitors.

[0083] The photoreceptor differentiation medium is made by mixing 97 parts by volume (pbv) of basal medium with 2 pbv of B27 vitamin A-free supplement and 1 pbv of N2 supplement, then adding BDNF, CNTF, retinoic acid, and a gamma secretase inhibitor (e.g., DAPT). The BDNF is present at a concentration of about 1 ng / mL to about 20 ng / mL, particularly about 10 ng / mL. The CNTF is present at a concentration of about 1 ng / mL to about 30 ng / mL (including about 5 ng / mL to about 25 ng / mL, or about 10 ng / mL to about 20 ng / mL), particularly about 20 ng / mL. The retinoic acid is present at a concentration of about 0.1 μM to about 5 μM, particularly about 0.5 μM. The gamma secretase inhibitor is present at a concentration of about 5 μM to about 15 μM, particularly about 10 μM. The photoreceptor differentiation medium does not contain TGFβ inhibitors or Wnt inhibitors.

[0084] Stem cells are first plated onto the laminin matrix / cell culture substrate made from one or two laminins as described above. The stem cells are typically applied as a monolayer, with approximately 10,000 cells / cm. 2 The particles can be plated at a density of 0.1 to 100 μm.

[0085] Differentiation is then initiated by applying the neural induction medium to the plated stem cells. The cells are cultured in the neural induction medium for a first period of about 120 hours to about 168 hours, including about 144 hours (i.e., 6 days). The medium may be changed periodically, for example, every 48 hours.

[0086] The neural induction medium is then removed and photoreceptor differentiation medium is applied to the plated stem cells. The cells are cultured in the photoreceptor differentiation medium for a second period of about 288 hours (12 days) to about 816 hours (34 days). The medium may be changed periodically, for example, every 48 hours. The length of time of exposure to the photoreceptor differentiation medium may affect the maturity of the resulting cells. As a result, retinal progenitor cells or mature photoreceptor cells may be obtained. This occurs over a total period of about 20 days to about 40 days of differentiation and maturation to obtain the desired retinal photoreceptor cells (precursor or mature). The photoreceptor cells may then be transplanted into one or both eyes of the patient or used for other applications.

[0087] Differentiation of stem cells into the desired photoreceptor cells can be identified by a significant downregulation of pluripotency markers Oct3 / 4 and Nanog, and an upregulation of its marker PAX6 at 20 days after the initiation of differentiation. Its markers VSX2, CRX, and RCVRN are upregulated at 30 days after the initiation of differentiation. These can be quantified by qPCR or immunostaining.

[0088] The method disclosed herein is robust to differentiating human embryonic stem cells into photoreceptors in a chemically defined and xenogeneic component-free culture environment with the expectation of transplanting clinically safe photoreceptors into patients. Thus, it provides a chemically defined and animal serum-free method that is GMP compatible and provides clinical grade photoreceptors.

[0089] Certain retinal progenitor cell subpopulations can also be identified by using gene or protein profiles generated at certain days after the start of differentiation. "Day X gene profile" includes the gene expression level of progenitor cells at day X, which is measured in units of gene counts per million (CPM) as calculated by the function calculateCPM in the scater 1.8.4 R package. In this regard, it is expected that the expression level of a given gene will vary during the differentiation process, and the measurement of the expression level can be used to identify subpopulations that may be particularly useful for certain purposes.

[0090] Four specific genetic profiles are contemplated. A first genetic profile is generated for any one of days 16-24 (also referred to herein as a "day 16-24 genetic profile"). A second genetic profile is generated for day 20 (also referred to herein as a "day 20 genetic profile"). Any reference to a day 16-24 genetic profile should also be considered as specifically referring to the day 20 genetic profile. A third genetic profile is generated for any one of days 26-34 (also referred to herein as a "day 26-34 genetic profile"). A fourth genetic profile is generated for day 30 (also referred to herein as a "day 30 genetic profile"). Any reference to a day 26-34 genetic profile should also be considered as specifically referring to the day 30 genetic profile.

[0091] Five specific subpopulations have been identified based on genetic profiles from days 16 to 24 and days 26 to 34.

[0092] In the first subpopulation (A), at least one of the genes CRX, C11orf96, NXPH4, NTS, DCT, PRDM1, NEUROD4, S100A13, RCVRN, FAM57B, SYT4, DLL3, SSTR2, CHRNA5, and ROBO2 is expressed in the gene profile at days 26-34. Combinations of any two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or fifteen of these genes are specifically contemplated. In some embodiments, the combination of expressed genes includes CRX and C11orf96.

[0093] In the second subpopulation (B), at least one of the genes STMN2, ONECUT2, ATOH7, ELAVL4, and GAP43 is expressed in the gene profile from day 26 to day 34. Combinations of any two, three, four, or five of these genes are specifically contemplated. In some embodiments, the combination of expressed genes includes STMN2 and ONECUT2.

[0094] In the third subpopulation (C), at least one of the genes CNTN2, NEFM, NEFL, PRPH, POU4F2, and CXCR4 is expressed in the gene profile from day 26 to day 34. Combinations of any two, three, four, five, or six of these genes are specifically contemplated. In some embodiments, the combination of expressed genes includes CNTN2 and POU4F2.

[0095] In the fourth subpopulation (D), at least one of the genes PAX6, SIX3, and SLC2A1 is expressed in the gene profile from day 26 to day 34. Any two or three of these genes are specifically contemplated. In some embodiments, the combination of expressed genes includes PAX6 and SIX3.

[0096] In the fifth subpopulation (E), at least one of the genes VSX2, PTH2, FZD5, RARRES2, DIO3, SOX2, and CYP1B1 is expressed in the gene profile from day 26 to day 34. Combinations of any two, three, four, five, six, or seven of these genes are specifically contemplated. In some embodiments, the combination of expressed genes includes VSX2 and CYP1B1.

[0097] In this disclosure, reference to a gene being "expressed" refers to a gene expression level where the gene has a minimum of 1 gene count per million (CPM). It is also noted that discussion of certain genes being expressed in these subpopulations should not be construed to mean that other genes are not expressed. For example, it is possible that the gene STMN2 is still expressed in subpopulation (A).

[0098] Furthermore, in these five subpopulations, the day 16-24 gene profile typically shows that at least one of the genes DAPL1, SIX6, SFRP2, LHX2, PAX6, CDH2, CLDN1, TRPM3, RELN, DCT, or PMEL is expressed. Combinations of any two, three, four, five, six, seven, eight, nine, ten, or eleven of these genes are specifically contemplated. In more specific embodiments, at least one of the genes SIX6, SFRP2, LHX2, PAX6, DCT, or PMEL is expressed, including combinations of any two, three, four, six, or six of these genes. In certain embodiments, PAX6 is expressed in the day 16-24 gene profile. The day 16-24 gene profile is used, if desired, to discard differentiating cells that do not terminate in the desired cell lineage.

[0099] In certain embodiments of subpopulation (A), the genetic profile from day 26 to day 34 indicates that (i) CRX is expressed at least 5 genes CPM and / or (ii) C11orf96 is expressed at least 5 genes CPM. In more specific embodiments, the genetic profile from day 26 to day 34 indicates that (i) CRX is expressed at least 10 genes CPM and / or (ii) C11orf96 is expressed at least 10 genes CPM.

[0100] In certain embodiments of subpopulation (B), the genetic profile from day 26 to day 34 indicates that (i) STMN2 is expressed at least 5 genes CPM and / or (ii) ONECUT2 is expressed at least 5 genes CPM. In more specific embodiments, the genetic profile from day 26 to day 34 indicates that (i) STMN2 is expressed at least 10 genes CPM and / or (ii) ONECUT2 is expressed at least 10 genes CPM.

[0101] In certain embodiments of subpopulation (C), the genetic profile from day 26 to day 34 indicates that (i) CNTN2 is expressed at least 5 genes CPM and / or (ii) POU4F2 is expressed at least 5 genes CPM. In more specific embodiments, the genetic profile from day 26 to day 34 indicates that (i) CNTN2 is expressed at least 10 genes CPM and / or (ii) POU4F2 is expressed at least 10 genes CPM.

[0102] In certain embodiments of subpopulation (D), the genetic profile from day 26 to day 34 indicates that (i) PAX6 is expressed at least 5 genes CPM and / or (ii) SIX3 is expressed at least 5 genes CPM. In more specific embodiments, the genetic profile from day 26 to day 34 indicates that (i) PAX6 is expressed at least 10 genes CPM and / or (ii) SIX3 is expressed at least 10 genes CPM.

[0103] In certain embodiments of subpopulation (E), the genetic profile from day 26 to day 34 indicates that (i) VSX2 is expressed at least 5 genes CPM and / or (ii) CYP1B1 is expressed at least 5 genes CPM. In more specific embodiments, the genetic profile from day 26 to day 34 indicates that (i) VSX2 is expressed at least 10 genes CPM and / or (ii) CYP1B1 is expressed at least 10 genes CPM.

[0104] The present disclosure is further illustrated in the following non-limiting working examples, it being understood that these examples are intended to be illustrative only, and that the present disclosure is not intended to be limited to the materials, conditions, process parameters, etc., described therein. EXAMPLES

[0105] Example 1 Development of HEK cell lines overexpressing LN-523 and LN-323

[0106] A flow chart describing the steps for producing recombinant laminin-523 and laminin-323 is provided in FIG. 1A. Briefly, human recombinant laminin expression plasmids encoding laminin α3, β2, and γ3 chains and containing three different antibiotic resistance genes were produced and transfected sequentially into HEK cells. To produce LN-523, expression plasmids encoding laminin α5, β2, and γ3 chains were transfected sequentially into HEK cells. Stable clonal cell lines overexpressing the desired laminin chains were established. Third, potential positive clones were identified using qPCR and Western blot. Fourth, for the positive laminin clones, the cell culture medium was switched to serum-free medium. Fifth, the cell culture medium containing secreted laminin was filtered through gel. Finally, Western blot and mass spectrometry were performed to confirm the identity of the laminin chain.

[0107] Human embryonic kidney (HEK) 293 cells were cultured and maintained in basal medium consisting of DMEM-GlutaMAX, high glucose, pyruvate (Life Technologies) supplemented with 10% fetal bovine serum in the presence of Pen-Strep (Life Technologies). For GMP production of human LN-323 and LN-523 for therapeutic purposes, the cells were cultured in the presence of human serum (instead of fetal bovine serum).

[0108] Prior to transfection with the plasmid, HEK293 cells were seeded in the absence of Pen-Strep so that they reached approximately 70% confluence at the time of transfection. Human recombinant laminin plasmid (pcDNA3.1) containing human laminin gamma 3 chain was first transfected into HEK293 cells using Lipofectamine® 2000 reagent (Life Technologies) and Opti-MeM (Life Technologies). A clonal stable cell line, HEK003, was first established using cloning rings (Bel-Art) and hygromycin B selection. This was followed by transfection into HEK003 with a plasmid expressing laminin beta 2 chain. HEK023 was then established using geneticin (G418) and hygromycin B selection. Plasmids expressing laminin α5 and α3 chains were transfected separately into HEK023 clonal cell lines to generate HEK523 and HEK323 clonal cell lines, respectively, and the final HEK523 / 323 cell lines were selected by Zeocin, Geneticin (G418) and Hygromycin B.

[0109] The identity of the clonal cell lines was determined by quantitative polymerase chain reaction (qPCR) analysis using LAMA5, LAMA3, LAMB2 and LAMC3 gene primer pairs. Potential positive clonal cell lines, HEK523 and HEK323, were further expanded and their basal culture medium was switched to serum-free medium for one week. The medium was collected and Western blot analysis was performed to further confirm the identity of laminin protein produced by the positive clonal cell lines. The selected positive HEK523 and HEK323 clonal cell lines should secrete LN-523 and LN-323 into the medium, respectively. The medium was dialyzed in polyethylene glycol for 4-5 days at 4°C. The LN-523 and LN-323-containing medium was concentrated in Amico centrifuge tubes and protein purification was performed using AKM through XK26 / 100 columns. The retina-specific laminin isoforms were analyzed by Western blot and mass spectrometry using a TA Chromatography System (GE Healthcare Life Sciences).

[0110] FIG 1B is a Western blot showing the presence of laminin α5, β2, and γ3 chains in purified fractions or portions of LN-523. Figure ID is a chromatogram illustrating the protein elution profile of the LN-523 clone using the Chromatography System. Figure ID is an LC-MS / MS (liquid chromatography-mass spectrometry) result showing the presence of laminin α5, β2, and γ3 chains.

[0111] FIG 1E is a Western blot showing the presence of laminin α3, β2, and γ3 chains in purified fractions or portions of LN-323. Figure 1G is a chromatogram illustrating the protein elution profile of the LN-323 clone using the Chromatography System. Figure 1G is an LC-MS / MS (liquid chromatography-mass spectrometry) result showing the presence of laminin α3, β2, and γ3 chains.

[0112] Maintenance of hESCs

[0113] Culture plates (Costar) were coated with purified human LN isoforms at 10 μg / mL overnight at 4° C. according to the manufacturer's instructions (BioLamina). Pluripotent human embryonic stem cells (hESCs) were seeded and expanded in vitro on LN-521 where they maintained pluripotency. The hESC line H1 (WiCell Research Institute) was cultured in monolayer on LN pre-coated plates and NutriStem hESC XF (Biological Industries, The H1 cell line was maintained in 10,000–20,000 cells / cm2. Once confluent, the cells were subcultured by trypsinization using TrypLESelect (GIBCO Invitrogen) for 8 min at 37°C and 5% CO2. 2 The cells were routinely passaged at 4°C for 1 h.

[0114] Photoreceptor Differentiation Protocol

[0115] 24-well tissue culture plates (Costar) were coated with either (A) LN-521 alone; (B) a mixture of LN-523 and LN-521 (2:1 ratio); or (C) a mixture of LN-323+LN-521 (2:1 ratio). The plates were coated to obtain a final concentration of 10 μg / mL. The hESCs (H1) were plated at a seeding density of approximately 70,000 cells / well and maintained in NutriStem with daily changes of fresh medium for 2 days.

[0116] The basal medium used throughout the differentiation process consisted of GMEM (Glasgow Minimum Essential Medium, Life Technologies) supplemented with 0.1 mM β-mercaptoethanol (Life Technologies), 1× non-essential amino acid solution (Gibco) and 1 mM pyruvate (Gibco).

[0117] After reaching approximately 70% confluence over two days, the NutriStem was replaced with neural induction medium (NIM). NIM consisted of 97% basal medium, 2% B27-vitamin A-free (Life Technologies) supplement, 1% N2 supplement (CTS, Life Technologies), 5 μM SB431542 (Sigma) and 5 μM CKI-7 (Sigma). NIM was replaced once every two days from day 0 (D0) to D6.

[0118] On day 7 (D7) of differentiation, NIM was replaced with photoreceptor differentiation medium (PRDM), which consisted of 97% basal medium, 2% B27-vitamin A-free supplement, 1% N2 supplement (CTS), 10 ng / ml human BDNF (brain-derived neurotrophic factor, PEPROTECH), 10 ng / ml human CNTF (ciliary neurotrophic factor, PROSPEC-TANY TECHNOGENE), 0.5 μM retinoic acid (Tocris Bioscience), and 10 μM DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester, Selleckchem). This medium was replaced every other day until D30.

[0119] Figure 2A is a diagram showing how hESCs are differentiated into photoreceptors. Three cell cultures are shown: Nutristem (day 0) for culture prior to differentiation; neural induction medium; and photoreceptor differentiation medium. Three photographs showing cells at D0, D20, and D30 are also provided.

[0120] Figure 2B and Figure 2C are a set of five different graphs of cells grown on LN-523+LN-521 substrates. The top graph of Figure 2B compares the expression of markers OCT3 / 4, NANOG, BRA, MIXL1, SOX17, FOXA2, and PAX6 between D0 and D20 cells. OCT3 / 4 and NANOG are upregulated at D0, while PAX6 is upregulated at D20.

[0121] The bottom left graph of Figure 2B compares, from left to right, the expression of PAX6 for D0 LN-523+LN-521, D20 LN-523+LN-521, D20 LN-523 only, D30 LN-523+LN-521, and D30 LN-523 only. PAX6 is upregulated at D20 and D30 compared to D0.

[0122] The graph on the bottom right of Figure 2B compares, from left to right, expression of VSX2 (Visual System Homeobox 2) for D0 LN-523+LN-521, D20 LN-523+LN-521, D20 LN-523 only, D30 LN-523+LN-521, and D30 LN-523 only. VSX2 is upregulated at D20 and D30 compared to D0.

[0123] The left graph in Figure 2C compares, from left to right, the expression of CRX (Cone Rod Homeobox protein) for D0 LN-523+LN-521, D20 LN-523+LN-521, D20 LN-523 only, D30 LN-523+LN-521, and D30 LN-523 only. CRX is upregulated at D20 and D30 compared to D0.

[0124] The right graph in Figure 2C compares, from left to right, expression of RCVRN (recoverin) for D0 LN-523+LN-521, D20 LN-523+LN-521, D20 LN-523 only, D30 LN-523+LN-521, and D30 LN-523 only. RCVRN is upregulated at D30 compared to D0.

[0125] Figure 2D and Figure 2E are a set of five different graphs of cells grown on LN-323+LN-521 substrates. The top graph in Figure 2D compares the expression of markers OCT3 / 4, NANOG, BRA, MIXL1, SOX17, FOXA2, and PAX6 between D0 and D20 cells. OCT3 / 4 and NANOG are upregulated at D0, while PAX6 is upregulated at D20.

[0126] The bottom left graph of Figure 2D compares, from left to right, the expression of PAX6 for D0 LN-323+LN-521, D20 LN-323+LN-521, D20 LN-323 only, D30 LN323+LN-521, and D30 LN-323 only. PAX6 is upregulated at D20 and D30 compared to D0.

[0127] The graph on the bottom right of Figure 2D compares, from left to right, expression of VSX2 for D0 LN-323+LN-521, D20 LN-323+LN-521, D20 LN-323 only, D30 LN-323+LN-521, and D30 LN323 only. VSX2 is upregulated at D20 and D30 compared to D0.

[0128] The left graph in Figure 2E compares, from left to right, expression of CRX for D0 LN-323+LN-521, D20 LN-323+LN-521, D20 LN-323 only, D30 LN-323+LN-521, and D30 LN-323 only. CRX is upregulated at D20 and D30 compared to D0.

[0129] The right graph in Figure 2E compares, from left to right, the expression of RCVRN for D0 LN-323+LN-521, D20 LN-323+LN-521, D20 LN-323 only, D30 LN-323+LN-521, and D30 LN-323 only. RCVRN is upregulated at D20 and D30 compared to D0.

[0130] Figure 2F and Figure 2G are a set of five different graphs of cells grown on LN-521 only substrate. The top graph of Figure 2F compares the expression of markers OCT3 / 4, NANOG, BRA, MIXL1, SOX17, FOXA2, and PAX6 between D0 and D20 cells. OCT3 / 4 and NANOG are upregulated at D0, while PAX6 is upregulated at D20.

[0131] The bottom left graph of Figure 2F compares, from left to right, the expression of PAX6 for D0, D20, and D30. PAX6 is upregulated at D20 and D30 compared to D0.

[0132] The graph on the bottom right of Figure 2F compares, from left to right, the expression of VSX2 for D0, D20, and D30. VSX2 is upregulated at D20 and D30 compared to D0.

[0133] The left graph in Figure 2G compares, from left to right, the expression of CRX on D0, D20, and D30. CRX is upregulated at D20 and D30 compared to D0.

[0134] The graph on the bottom right of Figure 2G compares, from left to right, the expression of RCVRN on D0, D20, and D30. RCVRN is upregulated at D20 and D30 compared to D0.

[0135] Figures 3A-3C are a set of photographs showing immunocytochemical analysis of D0 undifferentiated hESC and D38 hESC-derived retinal cells. Figure 3A is for cells grown on LN-523+LN-521 substrate. Figure 3B is for cells grown on LN-523+LN-521 substrate. Figure 3C is for cells grown on LN-521 only substrate. Each set contains 10 microscopic fields (scale bar = 20 μm). In each set, the top row shows the analysis of D0 cells for OCT4, D0 cells for PAX6, and D38 cells for PAX6. The second row shows these composited with DAPI. The third row shows the analysis of D38 cells for VSX2 and D38 cells for RCVRN. The fourth row shows these composited with DAPI. In D0 undifferentiated stem cells, OCT4 is expressed, but PAX6 (Paired box 6) is not expressed. In D38 differentiated cells, the markers PAX6, VSX2, and RCVRN are expressed.

[0136] Figure 3D compares the expression of markers PAX6, VSX2, CRX, and RCVRN on three laminin matrices: from left to right, LN-523:LN-521, LN-323:LN-521, and LN-521 only.

[0137] Example 2 Two independent single-cell RNA sequencing data sets were generated on retinal progenitor cells derived from H1 embryonic stem cells at day 20 and day 30. H1 cells were cultured for 20 and 30 days with the laminin protocol of Example 1. In each case, RNA was isolated using the 10x genomics kit and sequenced using the Illumina Hi-Seq3000 sequencing platform. Reads were mapped to the human genome (Ensembl version 90) and quantified using Cell Ranger 2.1.1 10x Genomics software. The Cell Ranger software was provided with a custom reference transcriptome generated by filtering the Ensembl transcriptome for gene biotypes: protein coding, lincRNA and antisense. Cell Ranger was run with the cell expectation parameter (expect-cells) set to 3000.

[0138] The Cell Ranger cell expectation numbers were 1,790 and 3,881 at days 20 and 30, respectively. The total number of reads were 631,803,330 and 687,721,993 at days 20 and 30, respectively. The percentage of reads mapped to the human genome was 97.1% and 96.8% at days 20 and 30, respectively. Cell Ranger returns the number of unique molecular identifiers (UMIs) associated with each gene (i.e., gene counts) and cell. The Cell Ranger output matrices (i.e., genes.tsv and barcodes.tsv) were then input into R and genes with zero counts in all cells were discarded.

[0139] Independent analyses were performed for each sample (i.e., retinal progenitor cells at day 20 and day 30). For each analysis, cell quality control was performed by removing: (a) cells with very low or very high library size (i.e., cells below and above the 5th and 99th percentiles of the total cell library size, respectively); (b) cells with a low number of detected genes (i.e., cells below the 5th percentile of the distribution formed by the total number of genes detected in each cell); and (c) cells with more than 10% of their total gene counts derived from mitochondrial genes. After removing cells that did not pass the cell quality control step, gene counts per million (CPM) were calculated for all genes. Gene CPM was calculated by providing the raw gene count matrix to the function calculateCPM of the scater 1.8.4 R package (McCarthy et al., 2017, Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics btw777). The function calculateCPM was run with the parameter use_size_factors set to FALSE.

[0140] In addition, in each separate analysis, we employed five gene quality control steps: (a) we kept only “detectable” genes, defined as genes detected with more than one transcript in at least 1% of all cells; (b) we removed genes with low mean expression in the data (i.e. genes with a raw mean gene count expression below 0.01; this cutoff was set based on the entire distribution of mean gene expression across all cells and all genes); (c) we removed genes with high dropout rates using the M3Drop 3.09 R package (Andrews, 2017, M3Drop: Michaelis-Menten Modelling of Dropouts in single-cell In this step, M3Drop false discovery rate (FDR) was used to rank all genes from low to high FDR and then the bottom 25% of genes (i.e., genes with the highest dropout rate) were removed; (d) outlier genes in the gene expression distribution (i.e., the "MALAT1" gene); and (e) genes encoded on the mitochondrial genome were removed.

[0141] After the gene quality control step, gene counts were normalized with the scran 1.8.4 R package (Lun et al., 2016, A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Research 5, 2122). Scran size factors were calculated from cell pools by pre-clustering the data with the quickCluster function. The output of this function was fed into the computeSumFactors function, and the Log2-transformed and normalized counts were then normalized with the scatter 1.8.4 package. R package (using default parameterization) (McCarthy et al., 2017, Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics btw777) function normalize. To account for cell cycle effects, G2M and G1 cell cycle scores were then calculated for each cell by using the cyclone function from the scater 1.8.4 R package (McCarthy et al., 2017). This function was fed with the set of human cell cycle genes provided in (Scialdone et al., 2015, Computational assignment of cell-cycle stage from single-cell transcriptome data. Methods 85, 54-61). The Log2-sran normalized gene counts were then corrected for cell cycle effects by submitting the counts and the covariates “cell cycle G2M score” and “cell cycle G1 score” to the function removeBatchEffect in the limma 3.36.3 R package (Ritchie et al., 2015, limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47-e47).

[0142] To identify genes marking cell subpopulations within a heterogeneous set of retinal progenitor cells, cell clustering was performed using the SC3 1.8 R package (Kiselev et al., 2017 SC3: consensus clustering of single-cell RNA-seq data. Nat. Methods 14, 483-486). Highly variable genes were identified using scran 1.8.4. The genes were identified by using the trendVar and decomposeVar functions of the R package (Lun et al., 2016). All genes were ranked by the resulting false discovery rate (FDR) value (from low to high) and the top 50% of genes (representing genes with the highest variability) were used for cell clustering in SC3. SC3 was performed using the Log2-scran normalized gene counts after correcting for cell cycle effects and a calculated set of only highly variable genes. SC3 was performed with an automated detection of the number of clusters (i.e., the K parameter, which is obtained by running the SC3 R package function sc3_estimate_k). This resulted in 19 and 21 cell clusters being identified in day 20 and day 30 retinal progenitor cells, respectively.

[0143] In day 20 retinal progenitor cells, marker genes were identified for cells expressing the PAX6 gene. In day 30 retinal progenitor cells, marker genes were identified for different cell subpopulations: (a) cells expressing PAX6; (b) cells expressing CRX; and (c) cells expressing VSX2.

[0144] To identify marker genes for these cell sets, the median expression level of the gene of interest (e.g., PAX6) was calculated in each of the two previously calculated cluster sets (19 and 21 cell clusters for days 20 and 30, respectively) by using the Log2-scran normalized gene counts after correcting for cell cycle effects. Clusters of cells with a median Log2 expression level of the gene of interest higher than 0.58 (this value corresponds to 0.5 in unlogarithmic gene counts) were then combined together to obtain a single gene of interest positive cell cluster. Pairwise expression differential analysis was then performed between all remaining clusters and the gene of interest positive cell cluster. This expression differential analysis was performed with edgeR 3.22.3 R package (Robinson et al., 2010, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140). EdgeR was used to calculate the unnormalized (raw) gene counts, scran 1.8.4 R package function sizeFactors, and size factors calculated with edgeR R package functions estimateDisp, glmQLFit and glmQLFTest. Only genes and cells that passed all the quality control steps above were used. To account for cell cycle effects, "cell cycle G2M score" and "cell cycle G1 score" were included in the edgeR model as calculated above. After performing differential expression, cell cluster marker genes were identified as genes that met the following two conditions: (a) pairwise Log2 fold change value higher than 2 when compared to all other clusters, and (b) Log2 median expression level higher than 1 in the cluster where the gene was labeled as a marker. This expression value corresponds to 1 in the unlogarithmized gene count.

[0145] For day 30 retinal progenitor cells, genetic markers were also calculated for two more cell clusters: (a) cell cluster number 1 (denoted as STMN2+ cluster) obtained when the SC3 algorithm was run with a K parameter of 2; (b) cell cluster number 3 (denoted as CNTN2+ cluster) obtained when the SC3 algorithm was run with a K parameter of 3. Genetic markers were calculated for these cell clusters by performing differential expression analysis and the steps described above.

[0146] The top genes marking each of these cell subpopulations (i.e., PAX6+ cells at day 20 and PAX6+ cells, VSX2+ cells, CRX+ cells, STMN2+ cells and CNTN2+ cells at day 30) were selected and their gene-gene pairwise Pearson correlation levels were plotted in histograms by using the function heatmap.2 of the R package gplots 3.0.1 (Warnes et al., 2016, gplots: Various R Programming Tools for Plotting Data) without scaling and with default parameterization to obtain Figures 5 and 6.

[0147] Day 20 and day 30 progenitor cells were visualized separately by using a t-distributed stochastic neighborhood embedding algorithm, t-SNE (McCarthy et al., 2017). t-SNE was calculated in two dimensions and by providing Log2scran normalized and cell cycle adjusted gene counts to the function plotTSNE in the scater 1.8.4 R package (McCarthy et al., 2017). The t-SNE perplexity parameter was set to the number of cells that passed quality control divided by 5. In the t-SNE graphs, each dot represents an individual cell, and cell subpopulations were also visualized in these graphs by mapping each cell to the expression levels of genes marking each of the subpopulations of retinal progenitor cells at day 20 and day 30 (Figures 4C-4D, Figures 7A-7J). The minimum and maximum colors were set to the minimum and maximum expression levels of each of the plotted genes. t-SNE graphs were also generated for day 20 retinal progenitor cells colored by expression levels of the genes NANOG and POU5F1 (Figures 4A-4B).

[0148] Day 20 retinal progenitor cells were found to lack expression of the genes NANOG and POU5F1 (Figures 4A-4B). Day 20 retinal progenitor cells were also found to express PAX6 in specific cell subpopulations (Figure 4C).

[0149] We also identified the following genetic markers for day 20 retinal progenitor cells belonging to this subpopulation of day 20 cells expressing PAX6 ( Fig. 5 ): DAPL1, SIX6, SFRP2, LHX2, PAX6, CDH2, CLDN1, TRPM3, RELN, DCT, and PMEL.

[0150] Five distinct cell subpopulations were identified in day 30 retinal progenitor cells (Figure 6), which were marked by the expression of the following genes:

[0151] (a) CRX, C11orf96, NXPH4, NTS, DCT, PRDM1, NEUROD4, S100A13, RCVRN, FAM57B, SYT4, DLL3, SSTR2, CHRNA5, and ROBO2 (CRX+ subpopulation, including cells highlighted in Figure 7A and Figure 7B);

[0152] (b) STMN2, ONECUT2, ATOH7, ELAVL4, and GAP43 (STMN2+ subpopulation, including cells highlighted in Figure 7C and Figure 7D);

[0153] (c) CNTN2, NEFM, NEFL, PRPH, POU4F2, and CXCR4 (CNTN2+ subpopulation, including cells highlighted in Figure 7E and Figure 7F);

[0154] (d) PAX6, SIX3 and SLC2A1 (PAX6+ subpopulation, including cells highlighted in Figure 7G and Figure 7H); and

[0155] (e) VSX2, PTH2, FZD5, RARRES2, DIO3, SOX2 and CYP1B1 (VSX2+ subpopulation, including cells highlighted in Figure 7I and Figure 7J).

[0156] The present disclosure has been described with reference to exemplary embodiments. Modifications and alterations will occur to others upon reading and understanding the foregoing detailed description. It is intended that the present disclosure be construed as including all such modifications and alterations insofar as they come within the scope of the appended claims or equivalents thereof.

Claims

1. 1. A method for generating retinal photoreceptor progenitor cells or photoreceptors, the method comprising: plating pluripotent human stem cells onto a cell culture surface having a laminin matrix, wherein the laminin matrix comprises (i) a first laminin that is laminin-521, wherein the laminin-521 is an intact protein, and (ii) a second laminin selected from the group consisting of laminin-323 and laminin-523, wherein the second laminin is an intact protein; and culturing said pluripotent human stem cells to obtain said retinal photoreceptor progenitor cells or photoreceptors.

2. The pluripotent human stem cells are Culturing the cells for a first period of time in a neural induction medium comprising a TGFβ inhibitor and a Wnt inhibitor; and culturing the cells for a second period of time in a photoreceptor differentiation medium comprising brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), retinoic acid, and a gamma secretase inhibitor. The method of claim 1, wherein the culture is performed by

3. The method of claim 2 , wherein the first period of time is from about 120 hours to about 168 hours.

4. 4. The method of claim 2 or 3, wherein the second period of time is from about 288 hours to about 816 hours.

5. The neural induction medium comprises: 5 μM to 15 μM of said TGFβ inhibitor; and 5 μM to 15 μM of the Wnt inhibitor The method according to any one of claims 2 to 4, comprising:

6. the TGFβ inhibitor is SB431542; or The method of claim 5, wherein the Wnt inhibitor is CKI-7.

7. The photoreceptor differentiation medium comprises: 1 ng / mL to 20 ng / mL of said brain-derived neurotrophic factor (BDNF); 1 ng / mL to 30 ng / mL of said ciliary neurotrophic factor (CNTF); 0.1 μM to 5 μM of said retinoic acid; and 5 μM to 15 μM of the gamma secretase inhibitor The method according to any one of claims 2 to 6, comprising:

8. The method according to any one of claims 2 to 7, wherein the gamma secretase inhibitor is DAPT.

9. The method of any one of claims 1 to 8, wherein the weight ratio of the second laminin to the first laminin is from 1:1 to 4:1.

Citation Information

Patent Citations

  • Photoreceptors and photoreceptor precursors generated from pluripotent stem cells

    JP2016515382A

  • Method of producing retinal pigment epithelial cell

    WO2015053375A1

  • Preparation of photoreceptors for the treatment of retinal diseases

    WO2017021972A1

  • Methods of differentiating retinal cells

    WO2017091844A1